This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: Spinal muscular atrophy is a progressive neurodegenerative disorder that can be treated with intrathecal antisense oligonucleotide therapy (nusinersen). However, administration is often complicated by posterior spinal fusion and neuromuscular scoliosis, necessitating a transforaminal approach.
PURPOSE: To assess the safety profile of the transforaminal approach for intrathecal access.
DATA SOURCES: Searches of the PubMed, Web of Science, and SCOPUS databases.
STUDY SELECTION: Thirteen articles were selected based on inclusion of transforaminal access and appropriate clinical information about the procedure.
DATA ANALYSIS: Complications were taken from the included articles and aggregated based on Cardiovascular and Interventional Radiological Society of Europe scale adverse event grading.
DATA SYNTHESIS: Total number of complications and grade of complications were analyzed, by year and in total.
LIMITATIONS: Selection bias in publication, small patient population size, and variability of the procedure limits the available data.
CONCLUSIONS: Transforaminal approach is a safe alternative for intrathecal access in patients with spinal muscular atrophy and may be applicable to a larger patient population.
ABBREVIATIONS:
- CBCT
- conebeam CT
- CIRSE
- Cardiovascular and Interventional Radiological Society of Europe
- SMA
- spinal muscular atrophy
Footnotes
Financial support for this work was provided by the University of Wisconsin School of Medicine and Public Health, Herman and Gwendolyn Shapiro Foundation Summer Research Program.
Disclosures: Marissa Schoepp—RELATED: Grant: Shapiro Grant, Comments: summer research funding program for medical students at the University of Wisconsin. Anthony Kuner—UNRELATED: Consultancy: Avexis Inc, Comments: Research consultant.
- © 2021 by American Journal of Neuroradiology